Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2018 Dec 16:2018:1631263.
doi: 10.1155/2018/1631263. eCollection 2018.

Retinopathy, Neuropathy, and Subsequent Cardiovascular Events in Patients with Type 2 Diabetes and Acute Coronary Syndrome in the ELIXA: The Importance of Disease Duration

Jelena P Seferovic  1 , Rhonda Bentley-Lewis  2 , Brian Claggett  1 , Rafael Diaz  3 , Hertzel C Gerstein  4 , Lars V Køber  5 , Francesca C Lawson  6 , Eldrin F Lewis  1 , Aldo P Maggioni  7 , John J V McMurray  8 , Jeffrey L Probstfield  9 , Matthew C Riddle  10 , Scott D Solomon  1 , Jean-Claude Tardif  11 , Marc A Pfeffer  1
Affiliations
Randomized Controlled Trial

Retinopathy, Neuropathy, and Subsequent Cardiovascular Events in Patients with Type 2 Diabetes and Acute Coronary Syndrome in the ELIXA: The Importance of Disease Duration

Jelena P Seferovic et al. J Diabetes Res. .

Abstract

Introduction: We investigated the association of diabetic retinopathy and neuropathy with increased risk of recurrent cardiovascular (CV) events in 6068 patients with type 2 diabetes mellitus (T2DM) and recent acute coronary syndrome (ACS) enrolled in the Evaluation of Lixisenatide in Acute Coronary Syndrome (ELIXA).

Methods: History of retinopathy and neuropathy as well as duration of T2DM were self-reported at screening. Proportional hazards regression models were used to assess relationships between retinopathy, neuropathy, and recurrent CV events.

Results: At screening, retinopathy and neuropathy were reported in 10.7% and 17.5% of patients, respectively, while 5.7% reported both. When adjusted for randomized treatment only, both retinopathy and neuropathy were associated with a primary composite outcome (CV death, nonfatal MI, stroke, or hospitalization for unstable angina) (retinopathy: HR 1.44, 95% CI 1.19-1.75; neuropathy: HR 1.33, 95% CI 1.12-1.57), CV composite (CV death, nonfatal MI, stroke, hospitalization for heart failure (HF)) (retinopathy: HR 1.57, 95% CI 1.31-1.88; neuropathy: HR 1.38, 95% CI 1.19-1.62), myocardial infarction (retinopathy: HR 1.38, 95% CI 1.08-1.76; neuropathy: HR 1.26, 95% CI 1.02-1.54), HF hospitalization (retinopathy: HR 2.03, 95% CI 1.48-2.78; neuropathy: HR 1.71, 95% CI 1.30-2.27), and all-cause mortality (retinopathy: HR 1.65, 95% CI 1.28-2.12; neuropathy: HR 1.43, 95% CI 1.14-1.78). When included in the same model, and adjusted for T2DM duration, there were no independent associations of either with CV outcomes, while T2DM duration remained strongly associated with all outcomes. Addition of demographic characteristics and CV risk factors did not further alter these relationships.

Conclusions: In patients with T2DM and recent ACS, a history of retinopathy and/or neuropathy and longer T2DM duration could be considered clinical markers for high risk of recurrent CV events. This trial is registered with the ELIXA (Evaluation of Lixisenatide in Acute Coronary Syndrome), ClinicalTrials.gov registration number NCT01147250.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Prevalence of retinopathy and/or neuropathy.
Figure 2
Figure 2
Distribution of T2DM duration in all patients, patients with no retinopathy/neuropathy and patients with retinopathy and/or neuropathy.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Gerstein H. C. Glucose: a continuous risk factor for cardiovascular disease. Diabetic Medicine. 1997;14(Supplement 3):S25–S31. doi: 10.1002/(SICI)1096-9136(199708)14:3+<S25::AID-DIA441>3.3.CO;2-T. - DOI - PubMed
    1. Fox C. S., Sullivan L., D'Agostino RB Sr, Wilson P. W., Framingham Heart Study The significant effect of diabetes duration on coronary heart disease mortality: the Framingham Heart Study. Diabetes Care. 2004;27(3):704–708. doi: 10.2337/diacare.27.3.704. - DOI - PubMed
    1. for the ADVANCE Collaborative group, Zoungas S., Woodward M., et al. Impact of age, age at diagnosis and duration of diabetes on the risk of macrovascular and microvascular complications and death in type 2 diabetes. Diabetologia. 2014;57(12):2465–2474. doi: 10.1007/s00125-014-3369-7. - DOI - PubMed
    1. Tkác I. Effect of intensive glycemic control on cardiovascular outcomes and all-cause mortality in type 2 diabetes: overview and metaanalysis of five trials. Diabetes Research and Clinical Practice. 2009;86(Supplement 1):S57–S62. doi: 10.1016/S0168-8227(09)70011-7. - DOI - PubMed
    1. Tung T. H., Chen S. J., Lee F. L., Liu J. H., Lin C. H., Chou P. A community-based study for the utility values associated with diabetic retinopathy among type 2 diabetics in Kinmen, Taiwan. Diabetes Research and Clinical Practice. 2005;68(3):265–273. doi: 10.1016/j.diabres.2004.10.003. - DOI - PubMed

Publication types

Associated data